{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:02:22Z","timestamp":1790064142065,"version":"4.0.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.tube.2016.05.013","type":"journal-article","created":{"date-parts":[[2016,6,26]],"date-time":"2016-06-26T23:02:29Z","timestamp":1466982149000},"page":"S16-S20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"S1","title":["TB vaccines in clinical development"],"prefix":"10.1016","volume":"99","author":[{"given":"Ann M.","family":"Ginsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Ruhwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2016.05.013_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1054\/tube.2001.0308","article-title":"Global Forum on TB vaccine research and development. World Health Organization, June 7\u20138 2001, Geneva","volume":"81","author":"Brennan","year":"2001","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2016.05.013_bib2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.tube.2016.05.013_bib3","series-title":"ClinicalTrials.gov [Internet]","article-title":"Study to evaluate the efficacy of GlaxoSmithKline (GSK) biologicals' candidate tuberculosis (TB) vaccine in adults","author":"GlaxoSmithKline","year":"2000"},{"key":"10.1016\/j.tube.2016.05.013_bib4","series-title":"ClinicalTrials.gov [Internet]","article-title":"Phase III Clinical Study of Efficacy and Safety of Vaccae\u2122 to Prevent Tuberculosis","author":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","year":"2000"},{"key":"10.1016\/j.tube.2016.05.013_bib5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/14760584.2014.905746","article-title":"The BCG replacement vaccine VPM1002: from drawing board to clinical trial","volume":"13","author":"Kaufmann","year":"2014","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.tube.2016.05.013_bib6","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1086\/592450","article-title":"A\u00a0new recombinant BCG vaccine safely induces significantly enhanced TB-specific immunity in human volunteers","volume":"198","author":"Hoft","year":"2008","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.tube.2016.05.013_bib7","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.vaccine.2015.01.058","article-title":"Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis","volume":"33","author":"Sander","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.tube.2016.05.013_bib8","series-title":"ClinicalTrials.gov [Internet]","article-title":"Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine","author":"Biofabri","year":"2000"},{"key":"10.1016\/j.tube.2016.05.013_bib9","doi-asserted-by":"crossref","first-page":"11290","DOI":"10.1038\/ncomms11290","article-title":"T-cell activation is an immune correlate of risk in BCG vaccinated infants","volume":"7","author":"Fletcher","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.tube.2016.05.013_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S2213-2600(15)00037-5","article-title":"MVA85A 030 trial investigators. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial","volume":"3","author":"Ndiaye","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.tube.2016.05.013_bib11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(14)70845-X","article-title":"Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial","volume":"14","author":"Satti","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tube.2016.05.013_bib12","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","article-title":"First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults","volume":"33","author":"Luabeya","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.tube.2016.05.013_bib13","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting","volume":"33","author":"Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.tube.2016.05.013_bib14","series-title":"ClinicalTrials.gov [Internet]","article-title":"Phase I trial of DAR-901","author":"Dartmouth-Hitchcock Medical Center","year":"2000"},{"key":"10.1016\/j.tube.2016.05.013_bib15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0b013e3283350f1b","article-title":"Prevention of tuberculosis in Bacille Calmette-Gu\u00e9rin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine","volume":"24","author":"von Reyn","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.tube.2016.05.013_bib16","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.1016\/j.vaccine.2010.09.041","article-title":"Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania","volume":"28","author":"Lahey","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.tube.2016.05.013_bib17","first-page":"155","article-title":"Protective inoculation against human tuberculosis with heat-killed tubercle bacilli","volume":"29","author":"Opie","year":"1939","journal-title":"Am J Hyg"},{"key":"10.1016\/j.tube.2016.05.013_bib18","doi-asserted-by":"crossref","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","article-title":"A\u00a0human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tube.2016.05.013_bib19","series-title":"ClinicalTrials.gov [Internet]","article-title":"Phase 1 clinical trial to evaluate the safety and immunogenicity of an adenovirus-based tuberculosis vaccine administered by aerosol","author":"McMaster University","year":"2000"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979216301913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979216301913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T12:26:18Z","timestamp":1717331178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979216301913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":19,"alternative-id":["S1472979216301913"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2016.05.013","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TB vaccines in clinical development","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2016.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}